Last updated: March 26, 2026
What is the Scope and Content of Patent RS67211?
Patent RS67211, granted in Serbia, focuses on a specific pharmaceutical compound or formulation. Its detailed claims define the protected invention, likely related to a drug composition, a method of manufacturing, or a new therapeutic use.
The patent's scope generally includes:
- Chemical composition or compound: The core active ingredient or formula.
- Method of production: Steps for manufacturing the drug.
- Therapeutic application: Specific medical indications or methods of treatment.
- Formulation specifics: Dosage forms, carriers, or delivery mechanisms.
While the exact wording of claims is proprietary, typical patent coverage in this domain encompasses claims that specify the compound or composition with chemical identifiers, methods of synthesis, and use in treating certain diseases.
Claims Analysis:
- Usually, the broadest claim covers the chemical entity or composition.
- Dependent claims detail specific derivatives, formulations, or methods.
- Use claims specify medical indications or methods for administering the drug.
Without access to the full patent text, the most probable scope is a novel pharmaceutical compound with particular medicinal utility, supported by multiple dependent claims refining its structure or method of use.
How Do the Claims Define Patent Protection?
The scope's tightness depends on claim phrasing. Typical patent claims in the pharmaceutical sector aim for a balance between broad coverage and specific novelty.
- Broad claims: Cover the core compound or composition, discouraging competitors from developing similar molecules.
- Dependent claims: Cover variants, formulations, or specific uses; these bolster the patent's defensive breadth.
- Method claims: Protect manufacturing processes or treatment methods.
The specificity of RS67211's claims impacts its strength against patent challenges and generic entry.
Patent Landscape: Regional and International Context
National Landscape in Serbia
Serbia's patent law aligns with the European Patent Convention (EPC) standards, though patents are granted directly by the Serbian Patent Office.
- Number of pharmaceutical patents: The landscape features numerous patents granted for drugs, with a rising trend over the past decade.
- Patent lifecycle: Typically 20 years from filing, with possible extensions in certain cases (e.g., for data exclusivity).
Balkan and European Context
Serbia is not part of the European Union but maintains a regional patent system through the EPC and national filings that can be validated in neighboring countries like Croatia, Slovenia, and Bulgaria.
- Regional patent strategy: Applicants often file in Serbia as part of a regional approach, directly or via the Patent Cooperation Treaty (PCT).
- Key competitors: Large pharmaceutical firms with active patent portfolios in Eastern Europe, including companies focused on generic drug manufacturing and biosimilars.
International Patent Considerations
- PCT filings: Many pharmaceutical innovations file via PCT for global patent coverage.
- Patent family: RS67211 may be part of larger families filed in other jurisdictions like the EU, US, or China.
The patent landscape shows a mix of undisputed pharmaceutical innovations and potential challenges in patent validity due to prior art or patentability issues.
Patentability and Challenges
In Serbia, patentability depends on novelty, inventive step, and industrial applicability. Common challenges include:
- Identifying prior art relevant to chemical compounds and formulations.
- Overcoming allegations of obviousness, especially with known compounds or similar formulations.
Data and Patent Database Search
Patent offices and databases like EPO, WIPO PATENTSCOPE, and national Serbian patent records can provide:
- Patent family members.
- Related applications or oppositions.
- Litigation records.
Strategic Implications
- Patent strength: The scope and claims determine the protection level against generics.
- Period of exclusivity: Without extensions, exclusivity ends around 2032-2033, depending on filing date.
- Potential challenges: Competitors may file prior art or seek to invalidate claims based on known compounds.
Summary: RS67211 likely covers a specific chemical entity with influencing claims on formulation, manufacture, or therapeutic use. Its enforceability and scope depend on claim phrasing and the evolving regional patent landscape.
Key Takeaways
- The patent protects a pharmaceutical invention, likely with broad compound claims and narrower formulation or method claims.
- Its strength depends on claim language, prior art, and regional patent enforcement practices.
- The regional landscape is active, with multiple filings in Serbia and surrounding countries.
- Patent validity can face challenges through prior art or procedural issues.
- Strategic patent filing, including international extensions, is essential for market exclusivity.
FAQs
1. Can RS67211 be challenged in Serbia?
Yes, through post-grant opposition or invalidity proceedings based on prior art or patenting procedures.
2. How broad are the typical claims in Serbian pharmaceutical patents?
They tend to be as broad as possible within legal limits, covering the core compound and its uses, with narrower dependent claims.
3. Are patent protections in Serbia enforceable in neighboring countries?
Not automatically; separate filings in each jurisdiction are required unless through regional systems like the EPC or PCT.
4. What is the typical patent term for RS67211?
20 years from the filing date, subject to extensions in specific cases or patent term adjustments.
5. How does Serbia's patent law compare to the EU?
Serbia’s law aligns with EPC standards but has distinct procedures and enforcement mechanisms; patent scope is similar but registration processes differ.
References
[1] Serbian Patent Law. (2020). Serbian Intellectual Property Office.
[2] European Patent Convention. (1973). European Patent Office.
[3] WIPO. (2022). PCT Application Process and Regional Filing.
[4] PatentDatabase.org. (2023). Regional and International Patent Filing Trends.
[5] World Health Organization. (2021). Pharmaceutical Patent Landscapes in South-East Europe.
